Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-15
2007-05-15
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S351000
Reexamination Certificate
active
10477876
ABSTRACT:
The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.
REFERENCES:
patent: WO 00/37502 (2000-06-01), None
patent: WO 00/63241 (2000-10-01), None
patent: WO 00/64460 (2000-11-01), None
patent: WO 01/24831 (2001-04-01), None
Ellison J. A. et al, “Matrix Remodeling After Stroke De Novo Expression of Matrix Proteins and Integrin Receptors”, Annals of the New Yor Academy of Sciences, New York Academy of Sciences, New York, NY, US vol. 890, 1999, pp. 204-222 XP001029484.
Julie A. Ellison et al, “Osteopontin and its Integrin Receptor Alphavbeta3 are Upregulated During Formation of the Glial Scar After Focal Stroke”, Stroke, American Heart Association, Dallas TX, US, vol. 29, No. 8, Aug. 1998, pp. 1698-1706, XP001029459.
Mun-Yong Lee et al, “Transient Upregulation of Osteopontin MRNA in Hippocampus and Striatum Following Global Forebrain Ischemia in Rats”, Neuroscience Letters, Limerick, vol. 271, No. 2, 1999, pp. 81-84, XP001029474.
(Prevention of Relapses and Disability by Interferon @B-1A Subcutaneously in Multiple Sclerosis) Study Group P, “Randomised Double-Blind PlaceBlo-Controlled Study of Interferon Beta-1A in Relapsing/Remitting Multiple Sclerosis”, vol. 352, No. 9139 Nov. 7, 1998, pp. 1498-1504, XP004265722.
Altschul S F et al, (1990) “Basic Local Alignment Search Tool” J Mol Biol. 215: 403-410.
Barres, B.A., and Raff, M.C. (Dec. 13, 1999). “Axonal Control Of Oligodendrocyte Development”. Journal of Cell Biology. 147(6): 1123-1128.
Barres, B.A., et al. (1993). “Multiple Extracellular Signals Are Required For Long-Term Oligodendrocyte Survival”. Development. 118(1): 283-295.
Bjartmar, C., et al (1999). “Axonal Pathology In Myelin Disorders”. Journal of Neurocytology. 28: 383-395.
Breighton, B and Hayden, MR: S, (Feb. 21, 1981). “Huntington's Chorea” Afr Med J.; 59(8): 250.
Dal Canto, M.C., et al (1995). “Two Models Of Multiple Sclerosis: Experimental Allergic Encephalomyelitis (EAE) and Theiler's Murine Encephalomyelitis Virus (TMEV) Infection. A Pathological And Immunological Comparison”. Microsc. Res. Tech. 32(3): 215-29.
Derynk R. et al., (1980). “Isolation And Structure Of A Human Fibroblast Interferon Gene” Nature 285: 542-547.
Devereux J et al, (1984). “A Comprehensive Set Of Sequence Analysis Programs For The VAX” Nucleic Acids Res, 12(1): 387-395.
Dubois-Dalcq, M., et al. (1999). “The Neurobiology Of X-Linked Adrenoleukodystrophy, A Demyelinating Peroxisomal Disorder”. Trends in Neurosciences 22(1): 4-12.
Dubois-Dalcq, M., and Murray, K. (2000). “Why Are Growth Factors Important In Oligodendrocyte Physiology?” Pathol Biol (Paris) 48(1): 80-86,.
Fernández, P.A., et al. (2000). “Evidence That Axon-Derived Neuregulin Promotes Oligodendrocyte Survival In The Developing Rat Optic Nerve”. Neuron 28(1): 81-90.
Franklin, R.J., and Hinks, G.L. (1999). “Understanding CNS Remyelination: Clues From Developmental And Regeneration Biology”. Journal of Neurosciences Research 58(2): 207-213.
Grantham, (1974). “Amino Acid Difference Formula to Help Explain Protein Evolution”, Science. 185: 862-864.
Grinspan, J.B., et al. (1996). “Re-Entry Into The Cell Cycle Is Required For Bfgf-Induced Oligodendroglial Dedifferentiation And Survival”. Journal of Neuroscience Research. 46(4): 456-464.
Grinspan, J.B., et al (1993). “Trophic Effects Of Basic Fibroblast Growth Factor (bFGF) On Differentiated Oligodendroglia: A Mechanism For Regeneration Of The Oligodendroglial Lineage”. Journal of Neuroscience Research. 36(6): 672-680.
Hajihosseini, M., et al (Dec. 15, 1996). “Origin Of Oligodendrocytes Within The Human Spinal Cord”. Journal of Neuroscience. 16(24): 7981-7994.
Hartung, H.P., et al (1998). “Guillain-Barre Syndrome, CIDP And Other Chronic Immune-Mediated Neuropathies”. Current Opinion in Neurology. 11: 497-513.
Hiremath, M.M., et al (1998). “Microglial/macrophage Accumulation During Cuprizone-Induced Demyelination in C57BL/6 Mice”. Journal of Neuroimmunology. 92(1-2): 38-49.
Ichikawa H, et al (2000). “Osteopontin-Immunoreative Primary Sensory Neurons In The Rat Spinal And Trigeminal Nervous System”, Brain Research. 863(1-2):276-281.
Jung, M., et al (1995). “Lines Of Murine Oligodendroglial Precursor Cells Immortalized By An Activated Neu Tyrosine Kinase Show Distinct Degrees Of Interaction With Axons In Vitro And In Vivo”. European Journal of Neuroscience. 7(6): 1245-1265.
Kiefer et al. (Apr. 25, 1989). “The cDNA And Derived Amino Acid Sequence For Human Osteopontin”. Nucleic Acids Res. 17(8):3306.
Kon S, et al (2000). “Antibodies To Different Peptides In Osteopontin Reveal Complexities In The Various Secreted Forms”. Journal of Cellular Biochemistry. 77(3): 487-498.
Kon S, et al (2002). “Mapping Of Functional Epitopes Of Osteopontin By Monoclonal Antibodies Raised Against Defined Internal Sequences”. Journal of Cellular Biochemistry. 84(2): 420-432.
Kunicki, T.J., et al (1997). “Molecular Determinants of arg-gly-asp Ligand Specificity for b3 Integrins”. Journal of Biological Chemistry. 272(7): 4103-4107.
Lee, et al, (Aug. 20, 1999). “Transient Upregulation Of Osteopontin mRNA In Hippocampus And Striatum Following Global Forebrain Ischemia In Rats”. Neuroscience Letters 271(2):81-84.
Lipton, S. A., and Rosenberg, P. A. (Mar. 3, 1994). “Excitatory Amino Acids As A Final Common Pathway For Neurologic Disorders”. New England Journal of Medicine. 330: 613-22.
Loius, J.C., et al (1992). “CG-4 A New Bipontial Glial Cell Line From Rat Brain, Is Capable Of Differentiating In Vitro Into Either Mature Oligodendrocytes Or Type-2 Astrocytes”. Journal of Neuroscience Research 31: 193-204.
Lubetzki, C., et al, (1993). “Even In Culture, Oligodendrocytes Myelinate Solely Axons”. Proceedings of the National Academy of Sciences of the USA. 90:6820-6824.
Marchionni, M.A., et al, (1999). “Neuregulin In Neuron/Glial Interactions In The Central Nervous System. GGF2 Diminishes Autoimmune Demyelination, Promotes Oligodendrocyte Progenitor Expansion, And Enhances Remyelination”. Advances in Experimental and Medical Biology. 468: 283-295.
Mark et al. (Sep. 1984). “Site-Specific Mutagenesis Of The Human Fibroblast Interferon Gene”. Proc. Natl. Acad. Sci. USA., 81: 5662-5666.
Matthieu, J.M., et al, (1992). “Myelin Gene Expression During Demyelination And Remyelination In Aggregating Brain Cell Cultures”. Journal of Neuroimmunology. 40(2-3): 231-234.
McDonald; J.W., et al, (1998). “Oligodendrocytes From Forebrain Are Highly Vulnerable To AMPA/kainate Receptor-Mediated Excitotoxicity”. Nature Medicine. 4(3): 291-297.
Morell, P., et al, (1998). “Gene Expression In Brain During Cuprizone-Induced Demyelination And Remyelination”. Molecular and Cellular Neurosciences. 12(4/5): 220-227.
Nait-Oumesmar, et al, (1999). “Progenitor Cells Of The Adult Mouse Subventricular Zone Proliferate, Migrate And Differentiate Into Oligodendrocytes After Demyelination”. European Journal of Neuroscience. 11(12): 4357-4366.
Ng, W.P., et al, (1996). “Human Central Nervous System Myelin Inhibits Neurite Outgrowth”. Brain Research. 720(1-2): 17-24.
Noseworthy, J.H. (1999). “Progress In Determining The Causes And Treatment Of Multiple Sclerosis”. Nature. 399: A40-A47.
Oldberg et al., (Dec. 1986) “Cloning And Sequence Analysis Of Rat Bone Sialoprotein (Osteopontin) cDNA Reveals An Arg-Gly-Asp Cell-Binding Sequence”. Proc Natl Acad Sci USA. 83(23):8819-8823.
Pantoni, L., et al, (1996). “Cerebral White Matter Is Highly Vulnerable To Ischemia”. Stroke. 27(9): 1641-1646.
Pearson W
Bernasconi Lilia
Boschert Ursula
Feger Georg
Papoian Ruben
Selvaraju Raghuram
Applied Research Systems ARS Holding N.V.
Browdy and Neimark PLLC
Carlson Karen Cochrane
LandOfFree
Use of osteopontin for the treatment and/or prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of osteopontin for the treatment and/or prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of osteopontin for the treatment and/or prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3820725